Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biophytis S.A. (BPTS)

0.4629   -0.012 (-2.55%) 01-27 15:59
Open: 0.410801 Pre. Close: 0.475
High: 0.4629 Low: 0.410801
Volume: 4,198 Market Cap: 9(M)

Technical analysis

as of: 2023-01-27 4:43:02 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.63     One year: 0.73
Support: Support1: 0.44    Support2: 0.37
Resistance: Resistance1: 0.54    Resistance2: 0.63
Pivot: 0.47
Moving Average: MA(5): 0.47     MA(20): 0.46
MA(100): 0.53     MA(250): 1.31
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 48.7     %D(3): 54.7
RSI: RSI(14): 49.3
52-week: High: 5.9  Low: 0.34
Average Vol(K): 3-Month: 130 (K)  10-Days: 23 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BPTS ] has closed above bottom band by 32.0%. Bollinger Bands are 58.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.46 - 0.47 0.47 - 0.47
Low: 0.41 - 0.41 0.41 - 0.41
Close: 0.46 - 0.46 0.46 - 0.47

Company Description

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Headline News

Thu, 19 Jan 2023
Stock Market Rebounds Slightly to Close at 52,626.42 bpts - THISDAY Newspapers

Thu, 19 Jan 2023
2023-01-19 | NDAQ:BPTS | Press Release | Biophytis SA - Stockhouse

Tue, 17 Jan 2023
February 2023 - Building Power Training Series: City Budget 101 - City of Detroit

Thu, 12 Jan 2023
Biophytis To Take Appropriate Measures After Receiving Nasdaq ... - BioSpace

Thu, 05 Jan 2023
Biophytis Announces Its Participation in Two Major Investor ... - BioSpace

Thu, 03 Nov 2022
Biophytis (NASDAQ:BPTS) Stock Jumps on Positive COVID-19 Drug ... - TipRanks

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 20 (M)
Shares Float 14 (M)
% Held by Insiders 0 (%)
% Held by Institutions 0.3 (%)
Shares Short 117 (K)
Shares Short P.Month 153 (K)

Stock Financials

EPS -2.78
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.41
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -52.9
Return on Equity (ttm) -783.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.31
Qtrly Earnings Growth 0
Operating Cash Flow -24 (M)
Levered Free Cash Flow -14 (M)

Stock Valuations

PE Ratio -0.17
PEG Ratio 0
Price to Book value 1.1
Price to Sales 0
Price to Cash Flow -0.4

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.